American Chemical Society - Philadelphia

As the world's largest private funder of Parkinson's research, The Michael J. Fox Foundation (MJFF) is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today.  Identification and validation of targets involved in PD pathogenesis is integral to ultimately developing and optimizing therapeutics.  Working with academic and industry partners, MJFF has supported the validation and therapeutic development efforts of over 100 targets including those that may have symptomatic benefit and putative targets with disease modifying potential.   This talk will provide an overview of the most critical targets identified to date, with an eye to the horizon and MJFF's endeavors to validate novel targets with therapeutic potential.

Authors: Sonal S. Das